Healios KK (JP:4593) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Healios K.K. has reached a key milestone in their joint research with AND medical, securing a 60 million yen payment as part of an ongoing agreement focused on producing culture supernatant using Healios’ technology. The company anticipates beginning monthly supply of 25 liters of culture supernatant to AND medical in fiscal year 2025, with the possibility of increasing production based on demand. This collaboration aims to advance regenerative medicine, with Healios providing its expertise in stem cell technology for new therapy development.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.